Qiagen NV
QGEN47.110USD
-0.280-0.59%
Close 06/13, 16:00（ET）Quotes delayed by 15 min
10.20BMarket Cap
122.05P/E TTM
More Details of Qiagen NV Company
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Company Info
Ticker SymbolQGEN
Company nameQiagen NV
IPO dateSep 01, 1996
Founded at1996
CEOMr. Thierry Bernard
Number of employees5765
Security typeOrdinary Share
Fiscal year-endSep 01
AddressHulsterweg 82
CityVENLO
Stock exchangeNYSE Consolidated
CountryNetherlands
Postal code5912 PL
Phone31773556600
Websitehttps://www.qiagen.com/
Ticker SymbolQGEN
IPO dateSep 01, 1996
Founded at1996
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
24.00
--
Ms. Eva van Pelt
Ms. Eva van Pelt
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Toralf Haag, Ph.D.
Dr. Toralf Haag, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Lawrence A. Rosen
Mr. Lawrence A. Rosen
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
By BusinessUSD
Name
Revenue
Proportion
Consumables and Related Revenues
1.76B
88.98%
Instrumentation
218.00M
11.02%
By RegionUSD
Name
Revenue
Proportion
United States
942.01M
47.62%
Europe & Middle East & Africa
648.49M
32.78%
Asia, Pacific & Rest of the World
298.15M
15.07%
Other Americas
89.56M
4.53%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables and Related Revenues
1.76B
88.98%
Instrumentation
218.00M
11.02%
Shareholding Stats
Updated: Sat, Jun 14
Updated: Sat, Jun 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
11.29%
MFS Investment Management
11.20%
BlackRock Institutional Trust Company, N.A.
9.64%
The Vanguard Group, Inc.
4.06%
Amundi Asset Management, SAS
1.94%
Other
61.87%
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
11.29%
MFS Investment Management
11.20%
BlackRock Institutional Trust Company, N.A.
9.64%
The Vanguard Group, Inc.
4.06%
Amundi Asset Management, SAS
1.94%
Other
61.87%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
46.01%
Investment Advisor
30.43%
Hedge Fund
3.22%
Research Firm
3.21%
Sovereign Wealth Fund
1.87%
Holding Company
1.17%
Bank and Trust
1.11%
Pension Fund
1.10%
Individual Investor
0.44%
Other
11.45%
Institutional Shareholding
Updated: Mon, Jan 20
Updated: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
987
158.50M
73.34%
-14.17M
2024Q4
1010
129.03M
59.70%
-70.06M
2024Q3
1010
183.22M
84.72%
-23.62M
2024Q2
1002
184.34M
84.75%
+8.40M
2024Q1
988
165.20M
76.61%
-7.18M
2023Q4
993
165.11M
76.72%
-10.52M
2023Q3
987
159.93M
74.32%
-12.21M
2023Q2
996
162.43M
75.49%
-6.05M
2023Q1
1001
160.07M
74.44%
-9.45M
2022Q4
1009
160.10M
74.55%
-10.38M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wellington Management Company, LLP
23.29M
10.78%
+2.11M
+9.98%
Jan 31, 2025
BlackRock Institutional Trust Company, N.A.
19.32M
8.94%
-13.86K
-0.07%
Mar 04, 2025
The Vanguard Group, Inc.
8.54M
3.95%
+77.90K
+0.92%
Dec 31, 2024
Amundi Asset Management, SAS
4.71M
2.18%
-798.61K
-14.50%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
3.96M
1.83%
-111.67K
-2.74%
Dec 31, 2024
DWS Investments UK Limited
2.14M
0.99%
+712.11K
+50.02%
Dec 31, 2024
Swedbank Robur Fonder AB
2.03M
0.94%
-95.44K
-4.49%
Feb 28, 2025
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
First Trust Nasdaq Lux Digi Health Solutions ETF
4.69%
Global X Genomics & Biotechnology ETF
3.96%
Invesco Biotechnology & Genome ETF
3.29%
ROBO Global Healthcare Technology & Innovation ETF
1.8%
Franklin Genomic Advancements ETF
1.75%
VanEck Biotech ETF
1.74%
iShares Health Innovation Active ETF
1.02%
Harbor Long-Short Equity ETF
0.9%
FlexShares US Quality Low Volatility Index Fund
0.85%
WisdomTree US AI Enhanced Value Fund
0.79%
View more
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion4.69%
Global X Genomics & Biotechnology ETF
Proportion3.96%
Invesco Biotechnology & Genome ETF
Proportion3.29%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.8%
Franklin Genomic Advancements ETF
Proportion1.75%
VanEck Biotech ETF
Proportion1.74%
iShares Health Innovation Active ETF
Proportion1.02%
Harbor Long-Short Equity ETF
Proportion0.9%
FlexShares US Quality Low Volatility Index Fund
Proportion0.85%
WisdomTree US AI Enhanced Value Fund
Proportion0.79%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
Date
Type
Ratio
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
